Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 8/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945801 | 0.88 | MAPT (0.50) | MAPTTP53POLBALOX15 | |
| SCHEMBL27424745 | 0.84 | POLB (0.42) | MAPTTP53POLBALOX15 | |
| SCHEMBL7241732 | 0.82 | MAPT (0.68) | MAPTTP53POLBALOX15 | |
| SCHEMBL9246649 | 0.82 | MAPT (0.67) | MAPTTP53POLBALOX15 | |
| SCHEMBL8914575 | 0.81 | TP53 (0.49) | MAPTTP53 | |
| SCHEMBL8084184 | 0.78 | MAPT (0.63) | MAPTTP53POLBALOX15 | |
| SCHEMBL9246654 | 0.78 | MAPT (0.62) | MAPTTP53POLBALOX15 | |
| SCHEMBL6952565 | 0.76 | ALOX15 (0.61) | MAPTTP53POLBALOX15 | |
| SCHEMBL8084548 | 0.76 | MAPT (0.59) | MAPTTP53POLBALOX15 | |
| SCHEMBL8912934 | 0.70 | CYP2C9 (0.49) | MAPTTP53ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6630494-B2 | Treatment for central degenerative disorders, brain power disorders, depressions, and for prophylaxis of cerebral circulatory disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | US | disclosed |
| US-6239155-B1 | TREATMENT OF CENTRAL DEGENERATIVE DISORDERS, AS DEMENTIAS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR AMYOTROPHIC LATERAL SCLEROSIS, MEMORY IMPAIRMENT, DEPRESSIONS, MIGRAINE, OF NEUROPATHIES, METABOLIC DISORDERS SUCH AS DIABETES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-29 | — | — | US | disclosed |
| US-6066655-A | FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, IN PARTICULAR AS CEREBRAL THERAPEUTICS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-05-23 | — | — | US | disclosed |
| US-5731333-A | LEARNING AND MEMORY ENHANCEMENT, ANTIDEPRESSANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | GRIK4, PKM, PDK4 | MAPT 565/4885TP53 4129/4885POLB 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.